Theranostics ishoko rekusanganisa kwekurapa uye kuongororwa (kushandisa imwe radionuclide kufananidzira mapundu uye yechipiri radionuclide kurapa mabundu nekuunza mwaranzi inouraya cancer). Chaizvoizvo, zvinoreva kunanga imwe chete receptor molecule pane cancer maseru ane maviri akasiyana radionuclides (kufungidzira uye kurapwa). Izvi ndezvekuwana nzira yekurapa chaiyo uye yega.
Masero ebundu ane goko, rinonzi membrane; kune mamwe mapuroteni akadai somatostatin receptor (SSTR2) pane tumor cell membrane inogona kushanda sechinangwa chemishonga yekenza.
Ga-68 DOTATOC mushonga weradioactive diagnostic mushonga unonangana neSSTR2. Ga-68 DOTATOC inobaiwa mutsinga yemurwere uye inofamba muropa rose kuenda kunhengo dzese nematishu emuviri. Kana murwere aine neuroendocrine bundu ine SSTR2 pabundu cell membranes, iyo Ga-68 DOTATOC inosunga kuSSTR2 uye bundu rinovhenekera paPET scan.
Kana kenza yeuroendocrine yaonekwa uchishandisa Ga68-DOTATOC PET scan, iyo Ga-68 inogona kutsiviwa neimwe radionuclide, yakadai selutetium-177 (Lu-177) kana yttrium-90 (Y-90), inogona kunanga nekuuraya bundu maseru. vane SSTR2 pa membranes yavo.
Therapeutic Y-90-DOTATOC uye Lu-177-DOTATATE zvose zvinogona kubaiwa mutsinga dzemurwere uye kufamba kune chero chikamu chemuviri chine SSTR2 mapuroteni. Iyi mishonga yekurapa inosunga kuSSTR2 mapuroteni sekiyi muvharo, zvichiita kuti mushonga upinde mumasero emamota uye uuraye nekukuvadza DNA yesero. Masero ane hutano akatenderedza bundu asina SSTR2 mapuroteni pa membrane yavo haabatike nemushonga.
Zano rakadaro rinobvumira oncologists kuti vafananidze matishu egomarara anorapika zvakanyanya, sarudza varwere vekurapa maapplication, nyatso tarisa kwainozounzwa varapi, uye tarisa kugona kweanorapa kudzikisa mapundu nekufamba kwenguva. Theranostics inopa oncologists neinoveli uye inoshanda zvakanyanya maturusi ekugadzira chaiyo nzira dzekurapa uye kufanotaura mabhenefiti eimwe nzira yekurapa zvichienderana nevarwere yakasarudzika mamorekuru uye genomic mbiri.
Izvi zvakare kudanwa yakanangana neradionuclide therapy sezvo yakanangwa kune chaiyo molecular tarisiro yeanoshanda cancer maseru. Naizvozvo, mwero wepamusoro weradiation unogona kunangana nebundu pasina kukanganisa akawanda akajairwa masero ane hutano.
Radiation therapy inogona kushanda zvakanyanya mukurapa gomarara, kana kuderedza zviratidzo muvarwere vane chirwere chegomarara chisingarapiki. Inosvika hafu yevarwere vese vegomarara vanowana kurapwa kwemwaranzi pane imwe nguva mukurapwa kwavo, iyo inoshandisa kunze kana mukati inounzwa x-rays, maproton kana mamwe masimba akakwira ekunongedza nekuparadza maseru egomarara. Nepo nzira dzakavandudzwa dzetekinoroji dzakadzikisira kuparara kwetishu, chinyakare radiotherapy ichiri kukonzera mhedzisiro inogona kunetsa kune vamwe varwere kushivirira. Uye zvakare, yechinyakare radiotherapy haikwanise kunanga inopfuura saiti imwe yechirwere, ichimisa kushandiswa kwayo kune varwere vane metastatic cancer. Nekudaro, yechinyakare radiotherapy inoramba iri imwe yeoncology yakasimba kwazvo yekurapa maturusi.
Iyi nyowani nzira yekurapa bundu - yakanangana neradionuclide therapy - iri kuvandudza kushandiswa kweradiation marapirwo mune chaiyo oncology uye kuendesa kirasi nyowani yekurapa cancer. Chinangwa chekunangwa kweradionuclide therapy budiriro ndechekubatanidza alpha-, beta- kana gamma-particle emitting isotopes - kana radionuclides - nemapeptides, masoja ekudzivirira chirwere, kana mamorekuru madiki, kugadzira marapirwo ane hunyanzvi hwepamusoro kune mamwe marudzi emamota. Inounzwa kumurwere nemutsinga, marapiro anonangwa eradionuclide akagadzirwa kuti afambe akananga kubundu kuti aendese nemwaranzi yekurapa nehungwaru hwepamusoro. Uku kunyatsojeka kunoitirwa kutarisa kuendeswa kwemwaranzi kune bundu tishu uku ichideredza kuratidzwa kwemwaranzi kune yakajairwa tishu.
Theranostics inogona kushanda mukurapa metastatic, isingashande mapundu ari padanho repamusoro rechirwere kusanganisira kenza yeprostate, neuroendocrine tumors dzenhengo dzakasiyana siyana semudumbu, chirwatata, matumbu & mahombe nemapapu. Chekupedzisira asi chisiri chidiki, post-operative ablation yezvakasara thyroid yasara uye kurapwa kwe metastatic thyroid cancer iri zvakare mune gamut of theranostics.
Magomarara ari pamusoro ane humbowo hwakakwana huripo parizvino hwekuti pane bhenefiti chaiyo mukushandisa radionuclide therapy. Nekudaro, mamwe akawanda magomarara anogona zvakare kuwana bhenefiti kana ataura mamwe marudzi ezvinotarirwa zvinogamuchirwa senge fibroblast activation protein (FAP) uye chemokine receptors (CXCR4), inogona kunangwa ne theranostics.
Inongofungidzirwa chete pazvinoitika zvekiriniki zvakasarudzika pazvikonzero zvetsitsi kubva pari zvino.
Kubudirira muCancer Care! Mutoro wegomarara urikura pasi rose unotaura nyaya inotyisa. Kurwisa kutyisidzira uku kuri kukura, Apollo Proton Cancer Center inopa yakakwana uye yakazara mhinduro. Sezvo kutarisirwa kwegomarara kwave chimwe chezvinhu zviri kukurumidza kukura zvehutano pasirese, tinotenda kuti zvakakosha kutsanangura patsva chinangwa chedu, kutangazve kuzvipira kwedu pachinangwa chepfungwa imwe chete - kurwisa cancer, kukunda cancer! APCC inomira senge chiedza chetariro kumamiriyoni, zvichivapa ushingi hwekumira uye kutarisa gomarara pasi.
Copyright © 2026 Apollo Proton Cancer Center. All Rights Reserved